ClinicalTrials.gg
RecruitingNCT07670325AKO-RUpdated Jun 26, 2026

Funcitonality and Safety of a Knee Device for Gait Rehabilitation in Neurological Patients

An interventional study of Exo-Assisted in Stroke, sponsored by Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 346 studies in Stroke with a site in Italy — 93 open to participants now, 106 under way, 3 of them phase 3. Stroke · Italy.

Planned enrollment
236th of 264
20 · median 76
Started
2026
with 14 others
No phase
208 of 346
66 open now
Primary completion
2026-11
later than 49 of 105 live
Registered
332nd of 346
by date

Among the 346 studies in Stroke with a site in Italy, this one is the 236th largest by planned enrollment of the 264 interventional ones that give a count, is one of 15 that started in 2026, is one of 208 with no phase, reaches primary completion later than 49 of the 105 other live ones, and was the 332nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

93 of the 346 studies in Stroke with a site in Italy are open now. Recruiting first, the newest first:

87 more — sign in →

All 93 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 346 studies in Stroke with a site in Italy, or all of them as a file.
02

Study summary

This clinical investigation aims to evaluate the safety, feasibility, and preliminary performance of the AKO-R wearable robotic device for knee assistance during walking. The study involves participants performing treadmill and overground gait training under supervised conditions, with the device providing assistive torque to support movement. Clinical and functional outcomes are assessed using validated measurement tools, while additional data are collected to characterize user performance and interaction with the device. The study is designed as an exploratory investigation to gather evidence supporting the clinical use and further development of the device. Primary outcomes regards safety of the device and preliminary clinical benefit on gait symmetry.

Read the detailed description

The study is structured in 5 sessions. The first and last session are the assessment. the 2nd session is the session for calibration of the exoskeleton parameters. The 3rd session is for exo familiarization and the 4th exo is for exo-assisted condition evaluation.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • exoskeleton
  • robotics rehabilitation
  • stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed stroke with fMRI
  • within 2 years from stroke event
  • FAC>= 3
  • height [1.5 - 2]m
  • weigth \<= 100 Kg

Exclusion criteria

Exclusion Criteria:

  • \<18
  • Pregnancy
  • Implanted cardiac devices, such as pacemakers or implantable cardioverter defibrillators (ICDs)
  • Recent or current participation in research studies that, in the opinion of the Principal Investigator, may affect the subject's response to the study intervention
  • Severe aphasia
  • MAS=4
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Exo-Assisted

    Patients perform gait training on treadmill and overground with assistance of the investigational device

    Device: Exo-Assisted

Interventions

  • DeviceExo-Assisted

    Participants perform gait training assiste by the knee exoskeletn investigational device

06

What researchers measure

Primary outcomes

  1. Number of device-related adverse events

    Time frame: through study completion, an average of 1 year

  2. Step Length Symmetry Index Change

    The Step Length Symmetry Index (SI) will be compared across conditions. Descriptive data are averaged across \>20 steps. Score closer to 0 means a better outcome.

    Time frame: Day 4

  3. Stance Time Symmetry Index Change

    The Stance Time Symmetry Index (SI) will be compared across conditions. Descriptive data are averaged across \>20 steps. Score closer to 0 means a better outcome.

    Time frame: Day 4

Secondary outcomes

  1. Range of motion Change

    The Range of motion (computed as difference between minimum and maximum joint angle in a step) will be compared across conditions. Descriptive data are averaged across \>20 steps

    Time frame: Day 4

  2. Self-selected velocity Change

    Effect of 3 sessions on self-selected velocity, compared with Session 1. Evaluated with 10 meter walking test

    Time frame: Day 5

  3. Endurance

    Effect of 3 sessions on endurance, compared with Session 1. Evaluated with 2 minute walking test.

    Time frame: Day 5

  4. Usability score

    Evaluated with System Usability Scale (SUS) questionnaire. The SUS score ranges from a minimum of 0 to a maximum of 100.

    Time frame: Day 5

  5. Acceptability

    Evaluated with Technology Acceptance Model (TAM) questionnaire. The TAM score goes from a minimum of 0 to a maximum score of 100.

    Time frame: Day 5

  6. Satisfaction Score

    Evaluated with Quebec User Evaluation of Satisfaction with assistive Technology 2.0 (QUEST 2.0). The QUEST goes from a minimum of 0 to a maximum of 100.

    Time frame: Day 5

07

Study locations

1 of 1 sites recruiting
  • Don Gnocchi - Centro "S. Maria della Provvidenza"
    Roma, RM 00166, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 5 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
Jun 26, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07670325
Lead sponsor
Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna
Collaborators
Istituti Clinici Scientifici Maugeri SpA, Fondazione Don Carlo Gnocchi ETS
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jun 22, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jun 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion